Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Hormone-receptor Positive and Triple Negative Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX)

Trial Profile

A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Hormone-receptor Positive and Triple Negative Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Cyclophosphamide (Primary) ; Pexastimogene devacirepvec (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms METROmaJX
  • Most Recent Events

    • 27 Oct 2020 Treatment arms changed from 4 to 6. Avelumab is added in assigned interventions of treatment arms. New primary endpoints added.
    • 21 Oct 2020 Planned number of patients changed from 118 to 197.
    • 21 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Nov 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top